Drug at center of $1.7B BMS, Five Prime partnership fails in Phase II pancreatic cancer study
BMS told Five Prime that it does not have current plans to further sponsor clinical development of the drug cabiralizumab after the failure of the combo trial, with BMS' Opdivo and chemotherapy, but would support some investigator-sponsored trials.